Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy

Therapy with immune checkpoint inhibitors (ICIs) has improved overall survival and cancer-related morbidity of cancer treatment even in cancer entities with poor prognosis. Since the approval of the first ICI, ipilimumab, for treatment of advanced melanoma by the Food and Drug Administration (FDA) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Möhn, Nora, Mahjoub, Susann, Gutzmer, Ralf, Satzger, Imke, Beutel, Gernot, Ivanyi, Philipp, Golpon, Heiko, Wattjes, Mike P., Stangel, Martin, Skripuletz, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749779/
https://www.ncbi.nlm.nih.gov/pubmed/33381178
http://dx.doi.org/10.1155/2020/8865054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749779/
https://www.ncbi.nlm.nih.gov/pubmed/33381178
http://dx.doi.org/10.1155/2020/8865054

Ejemplares similares